GoodRx Holdings, Inc.
For the period ended Sep 30, 2025. Filed Nov 4, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 4, 2025
What changed in Risk Factors?
Read the current filingPrevious report: 10-Q
Period ended 2025-06-30; filed 2025-08-06.
0001809519-25-000117
Item 1A. Risk FactorsCurrent report: 10-Q
Period ended 2025-09-30; filed 2025-11-04.
0001809519-25-000143
Item 1A. Risk FactorsThe baseline is this issuer’s latest earlier reporting period of the same form that was filed before the current report. A previous 10-Q is a different quarter, not a year-over-year comparison. Amendments are excluded.
Compared 36 previous paragraphs and 123 current paragraphs.
35 unchanged; 1 reworded; 87 added; 0 removed; 0 previous and 0 current paragraphs rearranged.
Tables are not compared: 0 previous and 0 current tables excluded. Dates, whitespace, punctuation and numbering changes are ignored; changes to financial figures remain significant.
A changed paragraph is not evidence that risk increased or decreased. An unchanged paragraph does not establish that risk stayed the same.
The current filing states there were no material changes to risk factors.
This is the filer’s own statement, not a conclusion from the comparison. Read its qualifications and the report it references.
Current filing’s statement
Factors" of our 2024 10-K. There have been no material changes to the risk factors previously disclosed in our 2024 10-K,
Added paragraphs (87)
Current report
The impact of healthcare reform legislation and other proposed or future changes impacting the healthcare
Current report
industry and healthcare spending on us is currently unknown, but may adversely affect our business, financial
Current report
Our revenue is dependent on the healthcare industry and could be affected by changes in healthcare spending and
Current report
policy. The healthcare industry is subject to changing political, regulatory and other influences. The Affordable Care Act (the
Current report
“ACA”), enacted in March 2010, made major changes in how healthcare is delivered and reimbursed, and increased access
Current report
to health insurance benefits to the uninsured and underinsured population of the United States. The ACA, among other
Current report
things, increased the number of individuals with Medicaid and private insurance coverage, implemented reimbursement
Current report
policies that tie payment to quality, facilitated the creation of accountable care organizations that may use capitation and
Current report
other alternative payment methodologies, strengthened enforcement of fraud and abuse laws and encouraged the use of
Current report
New and changing laws, regulations, executive orders and other governmental actions, particularly from the new
Current report
presidential administration, may also create uncertainty about how laws and regulations will be interpreted and applied.
Current report
Such changes can adversely affect our business by increasing our costs, reducing spending by our customers, limiting the
Current report
Company’s ability to pursue or offer new offerings, and requiring changes to our business. Regulatory changes and other
Current report
actions that materially adversely affect our business may be announced with little or no advance notice and we may not be
Current report
able to effectively mitigate all adverse impacts from such measures. Differing interpretations of such legal obligations can
Current report
expose us to significant fines, government investigations, litigation and reputational harm. If we are found to have violated
Current report
laws, regulations, or executive orders, it could materially adversely affect our business, reputation, results of operations and
Current report
In addition, recently there has been heightened governmental scrutiny of the manner in which pharma manufacturers
Current report
set prices for their marketed products, which has resulted in several U.S. congressional inquiries and proposed and enacted
Current report
federal and state legislation designed to, among other things, bring more transparency to medication pricing, reduce the cost
Current report
of prescription medications under government payor programs, and review the relationship between pricing and
Current report
manufacturer patient programs. For example, in August 2022, former President Biden signed the Inflation Reduction Act of
Current report
2022 (the “IRA”) into law. This statute marks the most significant action by Congress with respect to the pharmaceutical
Current report
industry since adoption of the ACA in 2010. Among other things, the IRA requires manufacturers of certain drugs to engage
Current report
in price negotiations with Medicare, with prices that can be negotiated subject to a cap; imposes rebates under Medicare
Current report
Part B and Medicare Part D to penalize price increases that outpace inflation (first due in 2023); redesigns the Medicare Part
Current report
D benefit (beginning in 2024); and replaces the Part D coverage gap discount program with a new manufacturer discounting
Current report
program (beginning in 2025). The Centers for Medicare & Medicaid Services has published the negotiated prices for the
Current report
initial ten drugs, which will first be effective in 2026, and has published the list of the subsequent 15 drugs that will be subject
Current report
to negotiation. The IRA permits the Secretary of the Department of Health and Human Services ("HHS") to implement many
Current report
of these provisions through guidance, as opposed to regulation, for the initial years. HHS has and will continue to issue and
Current report
update guidance as these programs are implemented, although the drug price negotiation program is currently subject to
Current report
legal challenges. In addition, the IRA delayed the final rule removing safe harbor protection for price reductions given by
Current report
pharmaceutical manufacturers to plan sponsors under Part D, either directly or through PBMs, unless the price reduction is
Current report
required by law, until 2032. In July 2025, the government enacted the One Big Beautiful Bill Act (the “OBBBA”), which
Current report
included reforms to programs such as Medicaid and restrictions for certain groups to access the Affordable Care Act
Current report
Marketplace. These changes may result in an increase in the number of individuals who are unable to access health
Showing the first 40 of 87 passages. Open the source sections for the rest.
Reworded paragraphs (1)
Previous wording
series of risks related to climate change” previously disclosed in our 2024 10-K. If any of these events occurs, our business
Current wording
series of risks related to climate change” previously disclosed in our 2024 10-K. If any of these events occur, our business